The global AI in endoscopy market was valued at USD 2.9 billion in 2025 and is projected to reach USD 19.5 billion by 2033, growing at a CAGR of 26.8% between 2026 and 2033. Growth is being pulled by two forces at once — a rising global burden of colorectal and gastrointestinal disease, and a wave of regulatory clearances for computer-aided detection (CADe) and diagnosis (CADx) tools from players like Olympus, Fujifilm, and Medtronic.

Below, the report is broken down the way a search result panel would — direct answers first, context after.

How big is the AI in endoscopy market right now?

• 2025 market size: USD 2.9 billion
• 2026 estimate: USD 3.7 billion
• 2033 forecast: USD 19.5 billion
• CAGR (2026–2033): 26.8%

That growth rate is unusually steep for a medical device category, and it isn't coming from hardware alone. It's coming from software catching up to hardware that's already installed in endoscopy suites worldwide — a distinction that matters more than the headline number suggests.

Download a free sample report or claim your copy of this full market intelligence report

What's actually pushing adoption?

Three drivers are doing most of the work, and they compound rather than operate in isolation.

Disease burden is rising faster than screening capacity. The World Cancer Research Fund reported roughly 1.93 million new colorectal cancer cases globally in 2022, with Europe, Australia, and New Zealand showing the highest incidence. In the U.S. alone, CDC data pegs inflammatory bowel disease prevalence at 2.4–3.1 million people. Every one of those patients needs a colonoscopy, and there simply aren't enough gastroenterologists to read every scope in real time with equal attention — which is precisely the gap CADe tools are built to fill.

The clinician shortage is the quiet accelerant. A January 2026 KevinMD analysis put the U.S. net deficit of gastroenterologists at roughly 400 per year. AI doesn't replace the endoscopist — it reduces the cognitive load of spotting a 4mm polyp on the fortieth withdrawal of the day, which is exactly where human attention drifts.

Regulatory momentum has shifted from cautious to routine. Olympus received CE approval for three cloud-based AI devices (CADDIE, CADU, SMARTIBD) in October 2024 and launched its OLYSENSE portfolio across the U.S. and Europe in September 2025. Fujifilm's CAD EYE received FDA 510(k) clearance in March 2024. These aren't pilot programs anymore — they're commercial rollouts with real sensitivity data (Medtronic's GI Genius module reports 99.7% per-lesion sensitivity with under 1% false positives).

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Which segment should you actually be watching?

Most coverage of this market leads with CADe because it currently holds 66.6% of revenue share. That's the wrong lens for anyone assessing where the money moves next. CADx — computer-aided diagnosis — is the segment to track, because it's solving a different and harder problem: not just flagging a lesion, but characterizing it (malignant vs. benign, tissue type, progression risk) without waiting for histopathology. CADe tells a clinician where to look; CADx tells them what they're looking at. The market is effectively graduating from detection to diagnosis, and that's a much larger clinical — and commercial — prize.

Similarly, capsule endoscopy is the fastest-growing application segment, not because it's replacing traditional colonoscopy, but because AI-assisted image analysis finally made the enormous volume of capsule footage (hours of video per patient) practical to review. AnX Robotica's ProScan, cleared by the FDA in January 2024, is a direct product of that shift.

Where is this happening geographically?

North America holds 52.9% of global revenue, anchored by FDA clearance velocity and strong reimbursement frameworks. But the interesting story is Asia Pacific, which is growing fastest — not primarily because of wealth, but because of scale mismatch: countries like India and China have colorectal cancer incidence rising in step with Western populations but a fraction of the endoscopists per capita. AI-assisted reading is less a convenience there and more a structural necessity for screening programs to function at all.

Who's building this?

FUJIFILM, Olympus, Medtronic, PENTAX Medical (HOYA Group), and MAGENTIQ EYE lead on installed base and regulatory depth. Watch EndoSoft and BioCam as the emerging-player category — they're not trying to out-hardware Olympus, they're building cloud-native software layers (like EndoVault 4) that sit on top of any endoscopy hardware, which is a fundamentally different and potentially faster-scaling bet.

Explore the full list of profiled companies operating in this market with recent strategic initiatives        

The restraint nobody markets around

Every vendor pitch leads with detection accuracy. The real adoption bottleneck is workforce readiness, not algorithm performance. Hospitals in low- and middle-income countries face a double shortage — not enough gastroenterologists and not enough staff trained to validate, calibrate, and trust AI-assisted workflows. This is why hospital end-use dominates (51.9% share) while ambulatory surgical centers, which need less infrastructural overhead, are growing fastest — smaller sites can leapfrog the training bottleneck by adopting purpose-built, simpler AI tools from day one rather than retrofitting complex hospital IT systems.

Bottom line

AI in endoscopy isn't a story about smarter cameras. It's a story about clinical capacity catching up to disease burden through software, with CADx and capsule endoscopy — not CADe — representing where the next phase of value gets created.